Astrana Health, Inc. — Form 8-K
Filed September 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Astrana Health raised its full-year 2026 Adjusted EBITDA guidance to $255–280M (midpoint $267.5M) from prior guidance, representing ~26% CAGR from FY2019. Q2 2026 delivered $972.5M revenue (+48.6% YoY) and $68.9M Adj. EBITDA. The company now operates across 16 markets with ~1.5M members in value-based care arrangements, 20,000+ providers, 81% of Q2 2026 capitation revenue from full-risk arrangements, and G&A improved 210 bps YoY to 5.6% of revenue through AI-native operating platform leverage.
Why this rating
Guidance raise of ~$50M EBITDA midpoint (~20% increase) is material relative to company's $1.1B market cap (~4.5% of equity value). Strong sequential execution, operating leverage momentum, and risk progression trajectory are business-affirming but execution within stated strategy. Magnitude and proof points meaningful for investor confidence but not transformational.
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.